Press Releases
// Mar 26, 2020
European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
// Mar 23, 2020
AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
// Feb 19, 2020
AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference
// Feb 12, 2020
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
// Dec 09, 2019
ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine
// Oct 01, 2019
ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research
// Sep 10, 2019
Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES
// Jul 25, 2019
Massachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies
// Jun 11, 2019
AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT
// May 22, 2019
